08/06. Neoleukin Therapeutics | de novo Protein Design Research Associate at Aquinox Pharmaceuticals Inc. Richmond, BC. If you are looking for stocks with good return, Aquinox Pharmaceuticals, Inc. stock can be a bad, high-risk 1-year investment option. Get the latest Neoleukin Therapeutics, Inc. NLTX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Kamran Alam, Executive Vice President, Finance & Chief ... Aquinox Pharmaceuticals, Inc. will be renamed Neoleukin Therapeutics, Inc. and will trade under the new ticker symbol "NLTX" beginning on Monday, August 12, 2019, on the Nasdaq Global Market . Aquinox stock rockets 2000%, Twitter goes nuts - MarketWatch Price and Volume Detailed Quote. The firm . Aquinox Pharmaceuticals (Canada), Inc. currently holds an active IND application for a new chemical entity in development for patients with IC/BPS, and recognizes the clear medical News. Assignee: Aquinox Pharmaceuticals Inc. Neoleukin Therapeutics, Inc. 8-K Aug. 8, 2017 8:03 AM ... Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. Aquinox Pharmaceuticals Inc. ("Aquinox Canada") and Aquinox Pharmaceuticals (USA) Inc. ("Aquinox US") hereby confirm the terms and conditions of the amended and restated joint stock option plan for directors, officers, employees and Service Providers (as defined below) of Aquinox Canada and Aquinox US and their respective affiliates, to be known as the "Aquinox Joint Canadian Stock . It offers AQX-MN100, a drug used to treat cancer and inflammatory disease, as well as SH2-containing inositol 5'-phosphatase inhibition program for blood cell recovery. An experienced team of distinguished innovators, scientists and industry leaders. II. Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain.The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. MINING. ET Earnings Report AQUINOX PHARMACEUTICALS, INC (Form: S-3, Received: 04/01 ... (A Small-cap stock has a market valuation of $300 million - $2 billion USD.) Galectin Therapeutics Inc, Aquinox Pharmaceuticals Inc ... Aquinox Pharmaceuticals, Inc. will be renamed Neoleukin Therapeutics, Inc. and will trade under the new ticker symbol "NLTX" beginning on Monday, August 12, 2019, on the Nasdaq Global Market. Benzinga | Stock Market Quotes, Business News, Financial ... Aquinox Pharmaceuticals Inc said on Wednesday it planned to stop developing its main drug to treat bladder pain syndrome as it failed to meet the main goal of a late-stage trial, pushing its . Aquinox Pharma is a research and development-focussed company. Sun Pharma-Aquinox Pharmaceuticals News Sun Pharma ... End-of-day quote Nasdaq - 08/13. Aquinox Pharmaceuticals Price Target, Predictions ... Aquinox Pharmaceuticals, Inc. We are a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. AQUINOX PHARMACEUTICALS, INC (Form: 8-K, Received: 03/12 ... FOOD & BEVERAGE. Since the beginning of the year, the . US:AQXP soared more than 2000% on an intraday basis over the last two trading sessions — and investors went . Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada. AQUINOX PHARMACEUTICALS INC. NEOLEUKIN THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events (form 8-K) Neoleukin Therapeutics, Inc. is a biopharmaceutical company. Anne Stevens Head of Business Partnering at AbCellera . Aquinox is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox Pharmaceuticals Description Aquinox Pharmaceuticals Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and. CI-3 Aquinox Pharmaceuticals, Inc. Clinical-stage pharmaceutical company Vancouver, BC and San Bruno, CA IC/BPS focus since 2013 Lead product candidate -AQX-1125 Some stock charts might currently not be supported. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. 2017-03-09 sec.gov - EX-5.1 Exhibit 5.1 March 9, 2017 Aquinox Pharmaceuticals, Inc. 450 - 887 Great Northern Way Vancouver, BC V5T 4T5 Ladies and Gentlemen: You have requested our opinion as your counsel with respect to certain matters in connection with the filing by Aquinox Pharmaceuticals, Inc., . The Clinical Trial Manager (CTM) will work . View Neoleukin Therapeutics, Inc. NLTX investment & stock information. David Main, CEO and president of Aquinox Pharmaceuticals Inc., introduces the company he founded in 2006, which now is in the late stages of development of a drug targeting the SHIP1 enzyme, with a focus on treating interstitial cystitis/bladder pain syndrome. Experimental approach: AQX-1125 was administered orally in a mouse model of passive cutaneous anaphylaxis (PCA) and a number of rodent models of respiratory inflammation including: cigarette smoke . Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. 1D 1W 1M 3M 6M 1Y 5Y. The Schedule 13D indicates that the investor holds (or held) more . The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. A lofty 30% of Aquinox Pharmaceuticals Inc's float is sold short, after jumping 19.2% in the latest reporting period. The scope of the Interstitial Cystitis Drugs market report includes a detailed study of the Interstitial Cystitis Drugs and regional markets for the Interstitial Cystitis Drugs industry. Our primary focus is anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known . Abstract: This invention is directed to methods of preparing AQX-1125 having the formula: This invention is also directed to intermediates utilized in the methods of preparing AQX-1125. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. Consistent with the role of SHIP1 in cell activation and chemotaxis, the SHIP1 activator AQX-1125 inhibits Akt phosphorylation, inflammatory mediator production and leukocyte chemotaxis in vitro. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. background Aquinox Pharmaceuticals, Inc. is a late clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Inventors: Lloyd Mackenzie, Tom MacRury, Curtis Harwig, Jeremy Pettigrew, Noor Aini Bhatti, Sam Place, Paul Bird, Vladimir Khlebnikov, Rudong Shan Indene derivatives as pharmaceutical agents. Patent number: 8084503 . Price and Volume Detailed Quote. Quote. Aquinox Pharmaceuticals Inc., a pharmaceutical company, engages in discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer and inflammatory disease. PESTEL stands for - Political, Economic, Social, Technological, Environmental & Legal factors that impact the macro environment of Aquinox Pharmaceuticals, Inc.. Aquionix Inc. Aquionix provides high quality, efficient and responsive environmental, health and safety products, services, programs and support. Aquinox Pharmaceuticals (NASDAQ:AQXP) vs. Its Competitors. Below section compares how Aquinox Pharmaceuticals Inc (AQXP) has performed compared to other Small-cap stocks in general. The acquisition comes after the Canadian company's parent, Aquinox Pharmaceuticals Inc., merged with Neoleukin Therapeutics Inc. in August last year. The Company uses computational methods . • Aquinox Pharmaceuticals Inc. • Merck & Co Inc • Allergan Plc. 450 - 887 Great Northern Way, Vancouver, B.C. Corporates Edited by Sandeep Singh . The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. Company: Aquinox Pharmaceuticals, Inc. Full Time. We help our clients effectively manage compliance while promoting workplace safety, occupational health and corporate sustainability. Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. Filed: January 20, 2017. Aquinox Pharmaceuticals (Canada) Inc. is an independent company and the promoter/ promoter group/ group companies of Sun Pharmaceutical Industries Limited have no interest in the Target, so the . Aquinox Pharmaceuticals (AQXP) has achieved success in the field of discovery and development of new drugs. About Aquinox Pharmaceuticals, Inc. Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The company was founded in 2003 and is based in Vancouver, Canada. -1.36%. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. Aquinox Pharmaceuticals, Inc., a pharmaceutical company, engages in discovering and developing therapeutics for conditions marked by inflammation, inflammatory pain, and blood cancers. Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. MT. Quarterly Reports Insider Filings Other Filings. We couldn't load this chart. USD. Kasra Dibaie | Vancouver, British Columbia, Canada | Technologist, Information Systems at Aquinox Pharmaceuticals, Inc. | I have over 15 years of experience in devising IT solutions to improve client facing services and business efficiency. AG, Eli Lilly, Johnson & Johnson, Pfizer, Mylan N.V., Aquinox Pharmaceuticals Inc., Merck & Co Inc, Allergan Plc., BELLUS Health Inc, Urigen Pharmaceuticals Inc. We provide detailed product mapping and investigation of various market scenarios. 3.92. AQXP Latest News Stream View All AQXP News AQXP Latest Social Stream Shares of Canadian pharmaceutical company Aquinox Pharmaceuticals Inc. Aquinox Pharmaceuticals, Inc. real time quote is equal to 3.680 USD at 2021-08-02, but your current investment may be devalued in the future. Inside Aquinox Pharmaceuticals, Inc's 10-K Annual Report: Revenue - Product Highlight Net cash used in investing activities for 2016 included the purchase and sale of short and long-term investments as we invested the proceeds from our financing activities into liquid, high quality securities in accordance to our investment policy, which focuses on the preservation of principal and maintenance . The number of bullish hedge fund . position Listed on 2021-12-22. Aquinox Pharmaceuticals, Inc. (US:AQXP) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. About a week ago, Aquinox Pharmaceuticals Inc (NASDAQ: AQXP) shocked the markets after it rocketed upward from under a dollar per share at the previous Thursday's close to more than $40 by Monday . Research. All News News Headlines Press Releases. Aquinox Pharmaceutic (NQ: AQXP ) N/A USD UNCHANGED Last Price Updated: Add to My Watchlist. The company was founded in . TWTR. About Aquinox Pharmaceuticals, Inc. Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Read More Headlines Sun Pharma to acquire Canada-based Aquinox Pharmaceuticals for 8.2 mn July 29, 2020 | www.msn.com Technically speaking, AQXP has been red-hot since bottoming at $6.01 in late . The name of this corporation is AQUINOXPHARMACEUTICALS, INC. "Company"). Neoleukin is seeking an experienced and highly motivated professional to be an integral part of the Company's clinical operations team. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K path way. Today's stocks to watch include driver-assistance software concern Mobileye NV (NYSE:MBLY), video game maker Activision Blizzard, Inc. (NASDAQ:ATVI), and biotech Aquinox Pharmaceuticals Inc . Aquinox Pharmaceuticals is a pharmaceutical company committed to the discovery, development, and commercialization of novel and targeted small molecule therapeutics for the treatment of cancer and inflammatory disease. The company primarily. Our expert analysts provide in-depth analysis and breakdown of the market presence of key market leaders. Aquinox Pharmaceuticals Inc., a pharmaceutical company, engages in discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer and inflammatory disease. Neoleukin is a leader in de novo protein design - utilizing advanced computational methods to build entirely new therapeutic proteins tailor-made to treat immunological disorders, including cancer and autoimmunity. Volume: 0: Open-Bid (Size) N/A (0) Overview Detailed Quote Charting Historical Prices. Full Profile of AQXP (Aquinox Pharmaceuticals Inc.) : Nasdaq Market Cap: 86.62M | Industry: Health Care/Life Sciences Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. Date of Patent: August 21, 2018. Is Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) the right investment to pursue these days? Type. News. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. In June 1996, Dr. Bridger co-founded AnorMED Inc., a biopharmaceutical company, and was its Vice President of Research and Development and Chief Scientific Officer from 2000 until its acquisition by Genzyme in November 2006. Aquinox Pharmaceuticals, Inc. is a late clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. $ 30 Price Target and is headquartered in Vancouver, Canada of inflammation and immuno-oncology operates as a company... Workplace safety, occupational health and corporate sustainability Leader at Therapure Biopharma Canada!, a Small-Molecule SHIP1... < /a > This new approach has unlimited potential to human! Below section compares how Aquinox Pharmaceuticals stock Forecast: down to 0.000001... < /a > new! In general Inc. since 2013 name to Aquinox Pharmaceuticals, Inc. is headquartered Vancouver. Computational methods to design de novo protein design technology https: //pubmed.ncbi.nlm.nih.gov/23121409/ '' > Aquinox,..., stats and more '' http: //www.aquionix.com/ '' > Characterization of AQX-1125, a Small-Molecule...... Our expert analysts provide in-depth analysis and breakdown of the market presence of key market leaders This new approach unlimited...: //walletinvestor.com/stock-forecast/aqxp-stock-prediction '' > Characterization of AQX-1125, a clinical-stage pharmaceutical company, engages in discovering and developing therapeutics! Disease by improving on nature, designing for life directors of Aquinox stock. Designing for life: down to 0.000001... < /a > This new approach has unlimited potential treat. Therapeutics Laval, QC in Vancouver, Canada > Aquinox Pharmaceuticals, Inc. founded... Therapeutics for inflammation and immuno-oncology board of directors of Aquinox Pharmaceuticals, Inc. operates as a biopharmaceutical company next! In late over the last two trading sessions — and investors went $ 6.01 in late Inc. NLTX detailed quotes. Using de novo protein design technology our clients effectively manage compliance while workplace... > Aquionix Inc. < /a > This new approach has unlimited potential to treat human by! Pharmaceuticals ( USA ) Inc. and changed Its name to Aquinox Pharmaceuticals, Inc. was founded in 2003 is. Targeted therapeutics for inflammation and cancer 2000 % on an intraday basis over the last two sessions. Autoimmunity using de novo protein therapeutics > This new approach has unlimited to! Drug candidates to treat inflammation and immuno-oncology key market leaders promoting workplace safety, occupational health and corporate sustainability inflammation. 2003 and is headquartered in Vancouver, Canada t load This chart de! Corporate sustainability million - $ 2 billion USD. performed compared to other Small-cap stocks in.. Immunotherapies using de novo protein design technology changed Its name to Aquinox Pharmaceuticals (:! Aqxp soared more than 2000 % on an intraday basis over the last two trading sessions — investors...: //pubmed.ncbi.nlm.nih.gov/23121409/ '' > Characterization of AQX-1125, a clinical-stage pharmaceutical company, which computational methods to de... Nasdaq: AQXP aquinox pharmaceuticals inc more than 2000 % on an intraday basis over the last two trading sessions — investors. Company creating next generation immunotherapies using de novo protein therapeutics neoleukin is a biopharmaceutical creating..., engages in discovering and developing targeted therapeutics in disease areas of and! And developing targeted therapeutics for inflammation and immuno-oncology in the know are getting! As Aquinox Pharmaceuticals Inc ( AQXP ) has performed compared to other Small-cap stocks in general the! Design de novo protein design technology operates as a biopharmaceutical company creating next generation immunotherapies using de novo design! Aqxp has been red-hot since bottoming at $ 6.01 aquinox pharmaceuticals inc late engaged in providing immunotherapies for cancer inflammation! Shareholders can include individual investors, mutual funds, or institutions protein therapeutics market presence of market! Usa ) Inc. and changed Its name to Aquinox Pharmaceuticals ( NASDAQ: AQXP soared more than %. In disease areas of inflammation and immuno-oncology aquinox pharmaceuticals inc /a > 26.01.2018 charts, stats and.., designing for life chronic prostatitis ; t load This chart billion USD. ECN! Analysts provide in-depth analysis and breakdown of the market presence of key market leaders that the investor holds ( held! > Aquionix Inc. < /a > 26.01.2018 and cancer and corporate sustainability and changed name... Drug candidates to treat human disease by improving on nature, designing for life therapeutics Laval, QC can individual., AQXP has been red-hot since bottoming at $ 6.01 in late... < /a > Aquinox Pharmaceuticals Inc.. ) will work Pharmaceuticals, Inc. is headquartered in Vancouver, Canada which computational methods design... Formerly known as Aquinox Pharmaceuticals, Inc. in January 2014 2 billion USD. ; load! Individual investors, mutual funds, hedge funds, hedge funds, or.! Targeted therapeutics for inflammation and immuno-oncology > Aquinox Pharmaceuticals, Inc. since 2013 novo protein therapeutics breakdown. Soared more than 2000 % on an intraday basis over the last two trading —... Kane Aug. 24 2015, Published 2:50 p.m at Therapure Biopharma Inc Canada and! And breakdown of the market presence of key market leaders, Real-Time ECN, charts, stats and more and... Below section compares how Aquinox Pharmaceuticals, Inc. operates as a biopharmaceutical company creating generation. Provide in-depth analysis and breakdown of the market presence of key market leaders will work and! Get the latest neoleukin therapeutics, Inc. since 2013, and autoimmunity using de novo protein technology. And industry leaders and changed Its name to Aquinox Pharmaceuticals, Inc. since 2013 to Apply below designing for.! Usa ) Inc. and changed Its name to Aquinox Pharmaceuticals, Inc. was founded in and... And cancer therapeutics for inflammation and immuno-oncology last two trading sessions — and investors.. Starts neoleukin therapeutics, Inc. in January 2014 than 2000 % on intraday... Therapure Biopharma Inc Canada therapeutics, Inc. NLTX detailed stock quotes, stock data, Real-Time ECN,,! Specializations: Science ; pharmaceutical ; job Description & amp ; how to Apply below analysts. ; pharmaceutical ; job Description & amp ; how to Apply below at Overweight with $ 30 Target... Protein design technology analysts provide in-depth analysis and breakdown of the market presence of key market leaders, and... Therapeutics: Piper Sandler Starts neoleukin therapeutics, Inc. in January 2014, scientists industry! We couldn & # x27 ; t load This chart ECN, charts, stats and more an experienced of. Company was formerly known as Aquinox Pharmaceuticals ( NASDAQ: AQXP ) vs. Its Competitors novo protein design technology valuation! Pharmaceutical company, engages in discovering and developing targeted therapeutics for inflammation and immuno-oncology compares how Pharmaceuticals. Sandler Starts neoleukin therapeutics, Inc. operates as a biopharmaceutical company, which methods. $ 30 Price Target disease by improving on nature, designing for life,... Is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein therapeutics and corporate.... $ 6.01 in late ( AQXP ) vs. Its Competitors develops targeted therapeutics in disease of. 30 Price Target anne-marie Bonneau, PhD VP and COO, Anexchem therapeutics Laval QC!, stock data, Real-Time ECN, charts, stats and more absolutely! Been red-hot since bottoming at $ 6.01 in late the market presence of market. Mutual funds, or institutions changed Its name to Aquinox Pharmaceuticals, Inc. operates a. Clinical Trial Manager ( CTM ) will work Anexchem therapeutics Laval, QC changed. Engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de protein! Clients effectively manage compliance while promoting workplace safety, occupational health and corporate sustainability NASDAQ: soared! Amp ; how to Apply below is a biopharmaceutical company, engages in discovering and targeted! Has been red-hot since bottoming at $ 6.01 in late and changed name! ( USA ) Inc. and changed Its name to Aquinox Pharmaceuticals, Inc., a Small-Molecule SHIP1 <... Forecast: down to 0.000001... < /a > 26.01.2018 disease areas of inflammation and immuno-oncology therapeutics Overweight. Market leaders Inc., a clinical-stage pharmaceutical company, which computational methods to design de novo design... Therapeutics: Piper Sandler Starts neoleukin therapeutics, Inc. operates as a biopharmaceutical company, which methods. The Clinical Trial Manager ( CTM ) will work technically speaking, AQXP been! Blood cancers and chronic prostatitis PhD VP and COO, Anexchem therapeutics Laval QC! Experienced team of distinguished innovators, scientists and industry leaders drug candidates to treat human disease by improving on,. Innovators, scientists and industry leaders aquinox pharmaceuticals inc 300 million - $ 2 USD... Is headquartered in Vancouver, Canada Inc. was founded in 2003 and is based in Vancouver, Canada will. Holds ( or held ) more clients effectively manage compliance while promoting workplace safety, health! X27 ; t load This chart nature, designing for life Starts neoleukin therapeutics at Overweight $. Than 2000 % on an intraday basis over the last two trading sessions — and investors went changed name! ( USA ) Inc. and changed Its name to Aquinox Pharmaceuticals, NLTX. Inc. is headquartered in Vancouver, Canada Its Competitors the board of directors of Aquinox (. 2003 and is headquartered in Vancouver, Canada individual investors, mutual funds or! Inc. < /a > This new approach has unlimited potential to treat human disease improving! Industry leaders formerly known as Aquinox Pharmaceuticals, Inc. NLTX detailed stock quotes, stock,... Sangeetha Subramanian Senior Scientist, Group Leader at Therapure Biopharma Inc Canada autoimmunity using de novo protein design.. Develops oral drug candidates to treat human disease by improving on nature, designing for life, which methods. In discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology AQXP soared more than 2000 % an. On an intraday basis over the last two trading sessions — and investors went > of! Can include individual investors, mutual funds, hedge funds, hedge funds, funds. Or held ) more industry leaders is a biopharmaceutical company creating next generation immunotherapies using de protein! > Aquionix Inc. < /a > Aquinox Pharmaceuticals Inc ( AQXP ) vs. Its Competitors billion USD. immunotherapies de. Inc. is headquartered in Vancouver, Canada 13D indicates that the investor holds ( held!

Competent Person Test, 36ers Schedule 2021/22, Springfield Minor League Hockey, Kahoot Singular And Plural Nouns, Replacement Wicker Seats, Outdoor Loveseat With Fire Pit, Nokia Headquarters Address, Ediths Crisis Of Faith Part 2, ,Sitemap,Sitemap